650 related articles for article (PubMed ID: 15561842)
21. daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Rose WE; Leonard SN; Sakoulas G; Kaatz GW; Zervos MJ; Sheth A; Carpenter CF; Rybak MJ
Antimicrob Agents Chemother; 2008 Mar; 52(3):831-6. PubMed ID: 17999971
[TBL] [Abstract][Full Text] [Related]
22. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
LaPlante KL; Woodmansee S
Antimicrob Agents Chemother; 2009 Sep; 53(9):3880-6. PubMed ID: 19564363
[TBL] [Abstract][Full Text] [Related]
23. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Leonard SN; Supple ME; Gandhi RG; Patel MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
[TBL] [Abstract][Full Text] [Related]
24. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Cha R; Rybak MJ
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
[TBL] [Abstract][Full Text] [Related]
25. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
[TBL] [Abstract][Full Text] [Related]
26. The safety and efficacy of linezolid and daptomycin as an additive in Optisol-GS against methicillin-resistant Staphylococcus aureus.
Li J; Feiz V; Vieira AC; Davis-Boozer D; Polage C
Cornea; 2012 May; 31(5):551-8. PubMed ID: 22378113
[TBL] [Abstract][Full Text] [Related]
27. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.
Lee DG; Murakami Y; Andes DR; Craig WA
Antimicrob Agents Chemother; 2013 Mar; 57(3):1434-41. PubMed ID: 23295932
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Rose WE; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418
[TBL] [Abstract][Full Text] [Related]
30. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
[TBL] [Abstract][Full Text] [Related]
31. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
[TBL] [Abstract][Full Text] [Related]
33. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Leonard SN; Cheung CM; Rybak MJ
Antimicrob Agents Chemother; 2008 Aug; 52(8):2974-6. PubMed ID: 18519721
[TBL] [Abstract][Full Text] [Related]
34. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Jacqueline C; Asseray N; Batard E; Le Mabecque V; Kergueris MF; Dube L; Bugnon D; Potel G; Caillon J
Int J Antimicrob Agents; 2004 Oct; 24(4):393-6. PubMed ID: 15380267
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
Houlihan HH; Mercier RC; Rybak MJ
Antimicrob Agents Chemother; 1997 Nov; 41(11):2497-501. PubMed ID: 9371356
[TBL] [Abstract][Full Text] [Related]
36. In vitro bactericidal activity of daptomycin against staphylococci.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
Housman ST; Sutherland CA; Nicolau DP
Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
[TBL] [Abstract][Full Text] [Related]
38. [Influence of inoculum size on MICs for methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus].
Miyake N; Kadowaki M; Sato Y; Eriguchi Y; Nagasaki Y; Harada Y; Uchida Y; Shimono N
Jpn J Antibiot; 2011 Aug; 64(4):231-7. PubMed ID: 22066347
[TBL] [Abstract][Full Text] [Related]
39. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
Arhin FF; Sarmiento I; Moeck G
Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
